Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173894 | 1.00 | CYP3A4 (0.73) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3077778 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3077775 | 0.87 | CYP3A4 (0.76) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3064813 | 0.87 | CYP3A4 (0.59) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3064808 | 0.87 | CYP3A4 (0.59) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2901546 | 0.86 | CYP3A4 (0.64) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2908700 | 0.86 | CYP3A4 (0.64) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2901545 | 0.85 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2901540 | 0.85 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2908695 | 0.85 | CYP3A4 (0.63) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1587787-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004065367-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | CYP3A4 932/4885CYP2C19 2217/4885CYP2C9 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.